Targeting dendritic cells for selective modulation of GVHD
Targeting dendritic cells for selective modulation of GVHD
批准号:
8349468
负责人:
Terry Fry
金额:
$24.89万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AllogenicAntibodiesAntigen TargetingAntigen-Presenting CellsAntigensB-LymphocytesBiological PreservationBloodBone MarrowBone Marrow TransplantationCD19 geneCellsCharacteristicsClinicCompetenceComplicationDendritic CellsDevelopmentDiabetes MellitusDisease ResistanceDonor Lymphocyte InfusionDrug usageFrequenciesFunctional disorderGenesGoalsITGAX geneImmuneImmune responseImmune systemImmunologic Deficiency SyndromesImmunologicsImmunosuppressionImmunosuppressive AgentsImmunotherapeutic agentInfectionInterferon Type IIInterleukin-10LaboratoriesMalignant NeoplasmsMediatingModalityModelingMonoclonal AntibodiesMorbidity - disease rateMouse StrainsMuramidaseMusMyeloid CellsOrganPathway interactionsPatientsPhagocytesPharmaceutical PreparationsPhenotypePhotopheresisPlayPopulationPopulation BiologyProductionProtocols documentationPublishingReactionRegimenRelapseReportingRiskRoleS100A8 geneS100A9 geneSTAT1 geneSeveritiesSeverity of illnessSignal TransductionStagingSystemic TherapyT cell responseT-Cell DepletionT-LymphocyteTissuesTranslatingTreatment EfficacyTumor AntigensVaccinationVaccinesWithdrawalWorkbasecancer cellcytokineexenatidegraft vs host diseasegraft vs leukemia effectin vitro testingin vivoinflammatory modulationinhibitor/antagonistinterferon gamma receptorinterferon gamma receptorsleukemiamortalitynovelpathogenpreventpromoterrecombinasereconstitutionresearch studyresponsetranscription factortumor
中文摘要
在目的1下进行的实验已经证明,即使相对温和的GVHD也可以减少对疫苗接种的定量T细胞免疫应答和对表达疫苗靶向抗原的肿瘤的功能性免疫应答。这项工作已经发表(Capitini等,Blood,2009),并证明了如果BMT要被优化为靶向恶性肿瘤的免疫方法的平台,则预防GVHD的重要性。 在目标2下,我们已经确定干扰素γ信号传导的抑制可以预防GVHD的发展(Capitini等,Blood 2009)。考虑到这种细胞因子在GVHD中的已知重要性,T细胞上干扰素γ信号传导的破坏导致GVHD严重程度的降低并不令人惊讶,但这种方法导致免疫缺陷。这些研究中的新发现是,骨髓来源的非T细胞上干扰素γ受体的选择性丧失也防止了由具有完整干扰素γ信号传导的T细胞介导的GVHD,并且保持了对疫苗的定性和功能性应答。我们还建立了体外单采血液成分术,这是目前在临床中用于治疗GVHD的一种方式,也通过调节DC群体中的IL-10产生来预防具有保留的疫苗应答的GVHD(Capitini等人,Biology of Blood and Marrow Transplantation,2011)。我们接下来研究了干扰素γ途径的其他成分是否可以靶向供体骨髓以预防GVHD。使用缺乏STAT 1(干扰素γ信号传导所必需的转录因子)的骨髓,我们已经证实,在骨髓源性细胞中干扰该途径可以预防GVHD,同时保留免疫能力。为了鉴定相关的骨髓源性细胞群,我们通过产生具有floxed STAT 1基因(从Lothar Hennighausen博士获得)的小鼠来选择性地靶向STAT 1,所述小鼠在非T细胞启动子(CD 11 c(DC表达)、溶菌酶(在所有吞噬细胞上)和CD 19(B细胞表达)下表达Cre重组酶。在来自这些供体的骨髓的接受者中,STAT 1基因(以及因此干扰素γ信号传导)可以在选择性细胞群中被消融。在所有这些细胞群中选择性丢失STAT 1不足以预防GVHD。有趣的是,在同种异体STAT 1缺陷骨髓的接受者中DC重建的进一步评估显示了扩增的浆细胞样DC(pDC)群体。此外,我们已经证实,STAT 1在迄今为止产生的所有Cre floxed STAT 1小鼠品系中保持完整。我们已经获得了pDC消耗抗体(来自Giorgio Trinchieri博士),以证实扩增的pDC群体负责在STAT 1缺陷骨髓受体中观察到的GVHD保护。初步研究表明,情况确实如此。基于这些发现,我们已经开始分析介导GVHD抗性的扩增的pDC的特征。初步研究表明,据报道为致耐受性的CD 9阴性pDC的频率增加。此外,S100 A8和S100 A9(与骨髓细胞中的抑制性表型相关的基因)的表达在来自STAT 1缺陷型骨髓受体的pDC中增加。使用S100 A8/S100 A9缺陷小鼠(通过Mackall实验室从Dimitri Gabrilovich博士获得),我们已经证实供体骨髓中这些基因的丢失会增加GVHD的严重程度。 目标3处于初始阶段。我们已经获得了选择性Stat 1抑制剂,并开始在体外测试这些。此外,我们使用了一种用于糖尿病患者的药物艾塞那肽对STAT 1的脱靶抑制,以证明在我们的小鼠模型中GVHD严重程度的降低。
英文摘要
The experiments conducted under aim 1 have demonstrated that even relatively mild GVHD can diminish quantitative T cell immune responses to vaccination and functional immune responses to tumors expressing vaccine-targeted antigens. This work has been published (Capitini et al, Blood, 2009) and demonstrated the importance of preventing GVHD if BMT is to be optimized as a platform for immunotherapeutic approaches targeting malignancy. Under aim 2, we have established that inhibition of interferon gamma signaling can prevent the development of GVHD (Capitini et al, Blood 2009). Reduction in GVHD severity with disruption of interferon gamma signaling on T cells was not surprising given the known importance of this cytokine in GVHD but this approach results in immunodeficiency. The novel finding in these studies was that selective loss of interferon gamma receptor on bone marrow-derived non-T cells also prevented GVHD mediated by T cells with intact interferon gamma signaling and did so with preservation of qualitative and functional responses to vaccines. We have also established the extracorporeal photopheresis, a modality currently being used in the clinic to treat GVHD, also prevented GVHD with preserved vaccine response via modulation of IL-10 production in DC populations (Capitini et al, Biology of Blood and Marrow Transplantation, 2011). We next studied whether other components of the interferon gamma pathway could be targeted in donor bone marrow to prevent GVHD. Using bone marrow deficient in STAT1, a transcription factor necessary for interferon gamma signaling, we have confirmed that interference with this pathway in bone marrow-derived cells can prevent GVHD with preserved immune competence. To identify the relevant bone-marrow-derived cell population, we have selectively targeted STAT1 by generating mice with a floxed STAT1 gene (obtained from Dr. Lothar Hennighausen) that express the Cre recombinase under non-T cell promoters (CD11c (DC expression), lysozyme (on all phagocytic cells), and CD19 (B cell expression). In recipients of bone marrow from these donors, the STAT1 gene (and, thus, interferon gamma signaling) can be ablated in selective cell populations. Selective loss of STAT1 in all of these cell populations was not sufficient to prevent GVHD. Interestingly, further assessment of DC reconstitution in recipients of allogeneic STAT1 deficient bone marrow demonstrated expanded plasmacytoid DC (pDC) populations. Further more, we have confirmed that STAT1 remained intact in all of the Cre floxed STAT1 mouse strains generated thus far. We have obtained pDC-depleting antibodies (from Dr. Giorgio Trinchieri) to confirm that the expanded pDC populations are responsible for the GVHD protection observed in recipients of STAT1-deficinet bone marrow. Preliminary studies indicate that this is case. Based on these findings we have begun to analyze the characteristics of the expanded pDCs mediating GVHD resistance. Preliminary studies indicate that there is an increase in the frequency of CD9 negative pDCs, reported to be tolerogenic. In addition, expression of S100A8 and S100A9, genes associated with a suppressive phenotype in myeloid cells, is increased in pDCs from STAT1 deficient bone marrow recipients. Using S100A8/S100A9 deficient mice (obtained from Dr. Dimitri Gabrilovich through the Mackall laboratory) we have confirmed that loss of these genes in donor bone marrow increases the severity of GVHD. Aim 3 is in the initial stage. We have obtained selective Stat1 inhibitors and are beginning to test these in vitro. In addition, we used off-target inhibition of STAT1 by exenatide, a drug used in patients with diabetes, to demonstrate reduction of GVHD severity in our murine models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing the graft versus leukemia effect for pediatric ALL
-
批准号:8157749
-
项目类别:
-
资助金额:$33.0万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants
-
批准号:8157750
-
项目类别:
-
资助金额:$13.2万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Adoptive T cell Therapy for Pediatric Leukemia
-
批准号:9153986
-
项目类别:
-
资助金额:$98.52万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
ALL immunobiology and the bone marrow niche
-
批准号:8938043
-
项目类别:
-
资助金额:$37.7万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Targeting dendritic cells for selective modulation of Graft-versus-Host Disease
-
批准号:8763453
-
项目类别:
-
资助金额:$16.63万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Adoptive T cell Therapy for Pediatric Leukemia
-
批准号:8938198
-
项目类别:
-
资助金额:$87.97万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Optimizing the graft versus leukemia effect for pediatric ALL
-
批准号:8763437
-
项目类别:
-
资助金额:$94.24万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants
-
批准号:8553086
-
项目类别:
-
资助金额:$26.06万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Optimizing the graft versus leukemia effect for pediatric ALL
-
批准号:8553085
-
项目类别:
-
资助金额:$84.69万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants
-
批准号:8349450
-
项目类别:
-
资助金额:$16.59万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Targeting dendritic cells for selective modulation of Graft-versus-Host Disease
-
批准号:8553103
-
项目类别:
-
资助金额:$19.54万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
ALL immunobiology and the bone marrow niche
-
批准号:9153848
-
项目类别:
-
资助金额:$42.22万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
ALL immunobiology and the bone marrow niche
-
批准号:9556514
-
项目类别:
-
资助金额:$46.32万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Optimizing the graft versus leukemia effect for pediatric ALL
-
批准号:8349449
-
项目类别:
-
资助金额:$41.48万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Adoptive T cell Therapy for Pediatric Leukemia
-
批准号:9779962
-
项目类别:
-
资助金额:$77.11万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
Targeting dendritic cells for selective modulation of GVHD
-
批准号:8157764
-
项目类别:
-
资助金额:$19.8万
-
财政年份:--
-
负责人:Terry Fry
-
依托单位:
海外基金